Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Minority-Interest-Expense" stands at -0.01 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Novartis AG's third quarter result of 0.002 Billion USD for the item "Minority Interest Expense" represents an increase of 111.76 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 0.002 Billion USD for the item "Minority Interest Expense" represents an increase of 150.00 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of -0.01 Billion USD for the item "Minority Interest Expense" represents an increase of 37.50 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.006 Billion United States Dollars compared to the value the year prior.
The 1 year change is -0.006 Billion United States Dollars.
The 3 year change is -0.008 Billion United States Dollars.
The 5 year change is 0.284 Billion United States Dollars.
The 10 year change is 9.79 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Minority Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Minority Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Minority Interest Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Minority Interest Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Minority Interest Expense | 280,205,508,085.11 |